Business context and reporting period
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing Immuno-STAT biologics for cancer, autoimmune disease and chronic infections. This Form 10-Q covers the quarter and nine months ended September 30, 2023. The company has not generated commercial product revenue and reports recurring operating losses.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $2.1 million | $0.1 million | $3.7 million | $1.1 million |
| Research and development expense | $9.9 million | $7.6 million | $29.9 million | $27.2 million |
| General and administrative expense | $3.6 million | $3.5 million | $12.1 million | $12.5 million |
| Net loss | $11.0 million | $11.0 million | $37.3 million | $38.4 million |
| Operating cash used | Not stated for quarter | Not stated for quarter | $29.0 million | $31.3 million |
At September 30, 2023, cash and cash equivalents were $54.7 million, with no marketable securities; restricted cash was $0.15 million. Current assets were $57.5 million and current liabilities $17.2 million. Total liabilities were $26.2 million, including debt with a net carrying value of $9.1 million. The term loan bears a floating rate, reported at 10.75% at quarter-end; scheduled principal payments are $1.0 million in 2023 and $4.0 million in each of 2024 and 2025. The loan is secured by substantially all assets other than intellectual property, which is subject to a negative pledge.
There is no meaningful product gross margin disclosed because the company has no commercial product sales. Operating loss was $11.4 million for Q3 and $38.3 million for the nine months. Basic and diluted loss per share was $0.24 for Q3 and $0.82 for the nine months.
Material changes versus comparable periods
- Collaboration revenue rose by $2.0 million in Q3 and $2.6 million for the nine months, primarily reflecting the Ono agreement signed in February 2023. Revenue is recognized for collaboration services; the company has not recognized milestone or royalty revenue to date.
- Research and development expense increased $2.3 million in Q3 and $2.7 million for the nine months, principally due to CUE-101 clinical activity and initiation of the CUE-102 Phase 1 trial.
- Nine-month net loss narrowed by $1.1 million year over year, while Q3 net loss was approximately unchanged. Higher collaboration revenue and interest income were partly offset by increased R&D spending and interest expense.
- Operating cash use decreased by $2.3 million year over year. Cash and cash equivalents increased from $51.6 million at December 31, 2022 to $54.7 million, supported by redemption of $25.0 million of short-term investments and $7.6 million of net ATM proceeds; these cash movements should not be read as operating cash generation.
- Common shares outstanding increased from 43.0 million at year-end 2022 to 45.1 million at September 30, 2023, including ATM issuance. The company also has outstanding warrants and stock options.
Outlook, management commentary and risks
Management stated that September 30 cash and cash equivalents were expected to fund operations for at least 12 months from issuance of the financial statements. The company also said future viability depends on obtaining additional capital; actual cash needs and runway may differ, and funding may not be available on acceptable terms. Management expects spending to rise as clinical and research programs advance.
- Ono funded CUE-401 research under a 24-month option period, with the company estimating it could complete the work in 18 months. Ono paid a $3.0 million upfront amount and reimburses eligible research costs. If Ono exercises its option, potential development and commercial milestones total up to approximately $220 million, plus royalties; these are contingent, not assured revenue.
- For CUE-101, management reported preliminary activity in small, non-comparator trials. In the combination study, the company reported a 47% overall response rate among 17 evaluable patients at the recommended dose, based on a September 27, 2023 data cutoff. The monotherapy cohort’s reported median overall survival estimate was 20.8 months. These findings are early and are not evidence of approval or established comparative benefit.
- For CUE-102, management reported 18 patients treated as of October 1, 2023, no observed dose-limiting toxicities, and preliminary disease-control observations. The company anticipated opening an expansion cohort in early 2024.
- Management is prioritizing CUE-101 and CUE-102 and seeking partners or alternative funding for other programs, including CUE-103, Neo-STAT, RDI-STAT and autoimmune programs.
- Key risks include clinical and regulatory uncertainty, reliance on third parties for trials and manufacturing, competition, intellectual-property protection, financing needs and potential dilution. The loan includes operating covenants and restricts financial flexibility. No material legal proceedings or accrued contingent liabilities were reported.
Disclosure controls and procedures were assessed as effective as of September 30, 2023; the filing reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the reported cash runway remains adequate as clinical spending, collaboration reimbursements and other cash needs evolve.
- Progress, enrollment, follow-up and regulatory plans for CUE-101 and CUE-102, and the limitations of the preliminary clinical data and historical comparisons.
- Ono’s CUE-401 research funding, option-period milestones and any decision to exercise its license option.
- Debt repayment requirements, floating interest costs, covenants and the required cash arrangement with the lender.
- Future financing capacity and dilution, including remaining ATM availability, outstanding warrants and options, and any new securities issuance.